一分钟看懂
这是一项关于白血病的III 期研究，登记的药物或干预包括Tacabrutideg；Pirtobrutinib，当前状态为招募中。登记地点显示中国北京、福州、兰州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tacabrutideg；Pirtobrutinib · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking Union Medical College Hospital · 北京
- Fujian Medical University Union Hospital · 福州
- The First Hospital of Lanzhou University · 兰州
- Sun Yat Sen University Cancer Center · 广州
- Jiangmen Central Hospital · 江门
- The First Affiliated Hospital of Guangxi Medical University · 南宁
- Guizhou Provincial Peoples Hospital · 贵阳
- The Fourth Hospital of Hebei Medical University East Branch · 石家庄
- The First Affiliated Hospital of Harbin Medical University · 哈尔滨
- Xuchang Central Hospitalluminghu Branch · 许昌
- Henan Cancer Hospital · 郑州
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technologychegu Branch · 武汉
- Affiliated Hospital of Nantong University · 南通
- The First Affiliated Hospital of Soochow University · 苏州
- Wuxi Peoples Hospital · 无锡
- The Affiliated Hospital of Xuzhou Medical University · 徐州
- The Second Affiliated Hospital of Nanchang University · 南昌
- The First Hospital of Jilin University · 长春
- The Second Hospital of Dalian Medical University · 大连
- Shengjing Hospital of China Medical University · 沈阳
- Qinghai University Affiliated Hospital · 西宁
- The Second Affiliated Hospital of Xian Jiaotong University · 西安
- Binzhou Medical University Hospital · 滨州
- Taian City Central Hospital · 泰安
- Renji Hospital Shanghai Jiao Tong University School of Medicine · 上海
- Shanxi Bethune Hospital · 太原
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital · 成都
- Dazhou Central Hospital · 达州
- The Affiliated Hospital of Southwest Medical University · 泸州
- Institute of Hematology and Hospital of Blood Disease · 天津
- First Affiliated Hospital of Kunming Medical University · 昆明
- The First Affiliated Hospital of Ningbo University · 宁波
- The First Affiliated Hospital of Wenzhou Medical University · 温州
公开的入选条件
- * Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 iwCLL criteria
- * Previously received treatment for CLL/SLL with a covalent Bruton tyrosine kinase inhibitor (cBTKi). Patients should have disease relapsed after or refractory to at least 1 line of therapy including a cBTKi.
- * Participants with SLL must have measurable disease by computed tomography/magnetic resonance imaging, defined as ≥ 1 lymph node \> 1.5 cm in longest diameter and measurable in 2 perpendicular diameters.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06973187；登记信息更新于 2026-09-11。